Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin
by
Contributor since / Followers
Contributor since / Followers
3 months ago
Spencer Platt/Getty Images News
- Tandem Diabetes Care (NASDAQ:TNDM) is up ~3% in Thursday midday trading after its t:slim X2 insulin pump was cleared for use with Eli Lilly’s (NYSE:LLY) ultra-rapid acting insulin Lyumjev (insulin lispro) in the European Union.
- While Lyumjev was authorized in 2020 to be used with insulin pumps in 2020, pump makers are required to perform tests to demonstrate compatibility with their automated insulin delivery devices.
- Both companies are working on gaining compatibility approval for Lyumjev with both t:slim X2 and Tandem Mobi pumps in other regions.